We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » India Intensifies Site Inspections in Response to Infant Deaths
India Intensifies Site Inspections in Response to Infant Deaths
May 13, 2009
The Drugs Controller General of India (DCGI) is increasing inspections of clinical trial sites rather than imposing new regulations in the wake of two recent incidents in which infants died in studies sponsored by multinational drug companies, an industry expert says.